Medtronic announces co-promotion agreement with cathworks, with path toward acquisition

Partnership underscores medtronic's commitment to investing in innovative technologies that support physicians and patients from diagnosis to treatment  cathworks' ffrangio® system provides diagnostic and physiologic information through artificial intelligence to potentially disrupt traditional ffr and revolutionize the management of coronary artery disease dublin and kefar sava, israel , july 12, 2022 /prnewswire/ -- medtronic plc (nyse:mdt), a global leader in healthcare technology, today announced it has entered into a strategic partnership agreement with cathworks, a privately held company headquartered in kefar sava, israel, which aims to transform how coronary artery disease (cad) is diagnosed and treated. as part of the agreement, medtronic will invest up to $75 million and immediately begin co-promotion of cathworks' ffrangio® system in the u.s., europe and japan, where it is commercially available.
MDT Ratings Summary
MDT Quant Ranking